Transcera utilizes sphingolipid membrane trafficking to enhance the delivery of biologic drugs, enabling mucosal absorption of large molecules and eliminating the need for injections. This approach addresses the limitations of traditional drug delivery methods by improving the pharmacokinetic and pharmacodynamic properties of therapeutic peptides, proteins, and oligonucleotides.
Funding
Funding not disclosed
Founders
Product
Problem
The absorption and distribution of biologic drugs are limited by epithelial and endothelial cell barriers, such as the intestinal mucosa and the blood-brain barrier. Traditional delivery methods often fail to overcome these obstacles, hindering the effectiveness of therapeutic peptides, proteins, and oligonucleotides.
Solution
Transcera leverages sphingolipid membrane trafficking to enhance the delivery of biologic drugs, enabling mucosal absorption of large molecules and eliminating the need for injections. This approach improves the pharmacokinetic and pharmacodynamic properties of therapeutic peptides, proteins, and oligonucleotides. Transcera's fully synthetic lipid vehicles can be tuned to enhance uptake and retention in different tissues, providing a more potent and durable effect. The company is also advancing intracellular delivery techniques to ensure precise and effective targeting of therapeutic molecules.
Target Audience
Transcera's primary customers are pharmaceutical companies and research institutions focused on developing and improving the delivery of biologic drugs.
Features
- Leverages transcytosis to enable mucosal absorption of large molecule therapeutics.
- Fully synthetic lipid vehicles can be tuned to enhance uptake and retention in different tissues.
- Intracellular delivery techniques ensure precise and effective targeting of therapeutic molecules.